BioPharmSignal logoBioPharmSignal

Biotech News

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Veru Inc (VERU)Veru IncEarnings

VERU (VERU) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is veru.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VERUVeru Inc2026-08-03 12:30 EST

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

VERUVeru Inc2026-07-27 12:10 EST

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Veru Inc

Cardiometabolic and Inflammation Company Veru develops late-stage small molecules for cardiometabolic and inflammatory diseases. Enobosarm Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with...

Recent company news

VERUVeru Inc2026-08-04 12:30 EST

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

VERUVeru Inc2026-08-03 12:30 EST

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

VERUVeru Inc2026-07-30 12:30 EST

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

VERUVeru Inc2026-07-27 12:10 EST

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

VERUVeru Inc2026-07-07 12:30 EST

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Stock data

Close
2.31 USD
Market cap
37.72M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States